Medacta Group (MOVE.SW) Stock Price

Medacta Group Price

🇨🇭SIX·CLOSED
149.06EUR
Market closed
Today +/-
Today %

Medacta Group (MOVE.SW) Stock | ISIN CH0468525222 | WKN A2PFTD. The current Medacta Group stock price is 149.06 EUR (2026). Revenue is 788.52 M EUR. Net income is 106.61 M EUR. The P/E ratio is 27.92. Market capitalization is 2.98 B EUR. Medacta Group operates in the Health sector.

Over the last 9 years Medacta Group grew revenue by 13.5% annually, reaching 683.83 M EUR. Earnings per share have grown at 10.4% per year over the last 9 years. For Medacta Group, the net margin of 14% is broadly stable versus 14.2% a few years ago. At today's price the dividend yield works out to roughly 0.23%. The payout ratio is around 12% of earnings. The dividend has grown at 8.8% per year over the past 3 years.

Medacta Group stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Medacta Group over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Medacta Group stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Medacta Group's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Medacta Group Stock Price History
DateMedacta Group Price
Access this data via the Eulerpool API
Get Free API Key

Medacta Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2016
219.05 M EUR
49.5 M EUR
39.22 M EUR
Jan 1, 2017
244.68 M EUR
49.66 M EUR
33.5 M EUR
Jan 1, 2018
272.61 M EUR
61.51 M EUR
45.75 M EUR
Jan 1, 2019
310.62 M EUR
57.81 M EUR
11.86 M EUR
Jan 1, 2020
302.49 M EUR
48.82 M EUR
37.09 M EUR
Jan 1, 2021
363.13 M EUR
66.59 M EUR
51.52 M EUR
Jan 1, 2022
437.12 M EUR
68.94 M EUR
46.25 M EUR
Jan 1, 2023
510.78 M EUR
75.72 M EUR
47.36 M EUR
Jan 1, 2024
590.58 M EUR
94.94 M EUR
72.89 M EUR
Jan 1, 2025
683.83 M EUR
116.36 M EUR
95.46 M EUR
Invalid Date
788.52 M EUR
133.65 M EUR
106.61 M EUR
Invalid Date
882.96 M EUR
152.74 M EUR
124.42 M EUR
Invalid Date
806.44 M EUR
128.92 M EUR
103.12 M EUR
Invalid Date
1.09 B EUR
185.42 M EUR
0 EUR
Invalid Date
1.18 B EUR
205.67 M EUR
0 EUR

Medacta Group Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 16, 2026, 6:12 AM
 
REVENUE (B EUR)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M EUR)
NET INCOME (M EUR)
NET INCOME GROWTH (%)
DIV. (EUR)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
202420252026e2027e2028e2029e2030e2031e
0.590.680.790.880.811.091.181.28
15.6915.7615.3711.93-8.6235.737.868.39
67.6367.258.2552.0456.9541.9638.935.89
399459459459459459459459
7295106124103---
53.1931.9411.5816.98-16.94–––
0.280.350.620.720.6---
3.721.4382.3516.13-16.67–––
19.9619.9719.9719.9719.9719.9719.9719.97
––––––––
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Medacta Group generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Medacta Group retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Medacta Group's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Medacta Group has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Medacta Group's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Medacta Group stock margins

The Medacta Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medacta Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medacta Group.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2016
75.12 %
22.6 %
17.9 %
Jan 1, 2017
74.63 %
20.3 %
13.69 %
Jan 1, 2018
74.82 %
22.56 %
16.78 %
Jan 1, 2019
73.05 %
18.61 %
3.82 %
Jan 1, 2020
70.72 %
16.14 %
12.26 %
Jan 1, 2021
71.94 %
18.34 %
14.19 %
Jan 1, 2022
69.83 %
15.77 %
10.58 %
Jan 1, 2023
68.1 %
14.82 %
9.27 %
Jan 1, 2024
67.64 %
16.08 %
12.34 %
Jan 1, 2025
67.18 %
17.02 %
13.96 %
Invalid Date
67.18 %
16.95 %
13.52 %
Invalid Date
67.18 %
17.3 %
14.09 %
Invalid Date
67.18 %
15.99 %
12.79 %

Medacta Group Stock Revenue, EBIT, Earnings per Share

The Medacta Group earnings per share therefore indicates how much revenue Medacta Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2016
10.95 EUR
2.47 EUR
1.96 EUR
Jan 1, 2017
12.23 EUR
2.48 EUR
1.67 EUR
Jan 1, 2018
13.63 EUR
3.08 EUR
2.29 EUR
Jan 1, 2019
15.53 EUR
2.89 EUR
0.59 EUR
Jan 1, 2020
15.12 EUR
2.44 EUR
1.85 EUR
Jan 1, 2021
18.15 EUR
3.33 EUR
2.58 EUR
Jan 1, 2022
21.86 EUR
3.45 EUR
2.31 EUR
Jan 1, 2023
25.55 EUR
3.79 EUR
2.37 EUR
Jan 1, 2024
29.59 EUR
4.76 EUR
3.65 EUR
Jan 1, 2025
34.24 EUR
5.83 EUR
4.78 EUR
Invalid Date
39.48 EUR
6.69 EUR
5.34 EUR
Invalid Date
44.21 EUR
7.65 EUR
6.23 EUR
Invalid Date
40.38 EUR
6.46 EUR
5.16 EUR

Medacta Group business model & stock analysis

The Medacta Group SA is a leading global company in the development, manufacturing, and marketing of medical devices and implants for the orthopedic industry. The company was founded in 1999 by Swiss entrepreneur Alberto Siccardi and is headquartered in Switzerland. The Medacta Group SA has its origins in one person - Alberto Siccardi. As a former athlete and successful entrepreneur, he had a vision that he put into action. He founded the Medacta Group and began focusing on the development and manufacturing of innovative orthopedic devices and implants. The Medacta Group has an innovative business model because the company is able to handle everything from research and development to marketing and sales of its products. This means that Medacta combines all steps from idea to end product under one roof and has complete control over the entire process. The Medacta Group SA is divided into three business areas: orthopedics, spine, and sports medicine. In the orthopedic field, the company manufactures hip and knee joint implants, as well as shoulder and elbow implants. Medacta also offers technologies that help extend the lifespan of artificial joints. In the spine field, the company provides instruments and implants for spine surgery. Medacta has a high level of expertise in this field and is known for innovative products that contribute to improving patient treatment. In the sports medicine field, the Medacta Group offers solutions for sports injuries. The company has developed a wide range of technologies and products that accelerate the healing process and support rehabilitation. Some of Medacta's most well-known products are the AMIS (Anterior Minimally Invasive Surgery) hip joint system and the GMK (General Medacta Knee) knee joint system. The AMIS system is a minimally invasive procedure for hip joint surgery that aims to shorten rehabilitation time and reduce the risk of complications. The GMK system is an innovative knee joint system that allows natural joint mechanics and approximates the natural knee pivot point. Medacta has also developed a range of software solutions that support surgeons in the planning and execution of operations. These solutions provide detailed visualizations and allow for precise planning of procedures. In conclusion, the Medacta Group SA is a global leader in the development and manufacturing of medical devices and implants for orthopedics, spine, and sports medicine. The company has an innovative business model that allows for complete control of the entire manufacturing process. Through the development of innovative products and technologies, the Medacta Group supports the treatment and rehabilitation of patients worldwide.

Medacta Group SWOT Analysis

Strengths

Medacta Group SA has several strengths that contribute to its success in the market. Firstly, the company possesses a strong reputation for its innovative medical devices and solutions. This reputation has been built through years of research and development, leading to high-quality products. Additionally, Medacta Group SA has established strong relationships with healthcare professionals and institutions globally, which allows for widespread distribution and adoption of its products.

Weaknesses

Despite its strengths, Medacta Group SA also faces certain weaknesses that need to be addressed. One major weakness is the company's limited geographic presence compared to some of its competitors. Medacta Group SA primarily operates in Europe and Asia, which limits its market reach and potential for growth in other regions. Another weakness is the company's heavy reliance on a few key products for its revenue. This lack of diversification exposes Medacta Group SA to potential market volatility and competitive threats in the long term.

Opportunities

There are several opportunities that Medacta Group SA can capitalize on to further enhance its market position. Firstly, the growing global demand for minimally invasive surgical procedures presents a significant opportunity for Medacta Group SA's innovative medical devices. By continuing to invest in research and development, the company can develop new products that cater to this trend and gain a competitive edge. Additionally, expanding into untapped markets such as North America and Latin America can help Medacta Group SA diversify its revenue streams and reduce its dependence on specific regions.

Threats

Despite the opportunities, Medacta Group SA faces several threats that may hinder its growth and profitability. One major threat is intense competition in the medical device industry. Competitors with larger market shares and broader product portfolios pose a challenge to Medacta Group SA's market position. Additionally, stringent regulatory requirements and the need for rigorous clinical trials can increase the time and cost of bringing new products to market, potentially impacting Medacta Group SA's ability to stay ahead of the competition. Lastly, economic downturns and healthcare budget constraints in key markets can reduce the demand for medical devices, affecting Medacta Group SA's sales and profitability.

Medacta Group Eulerpool Fair Value

Medacta Group historical P/E ratio, EBIT multiple, and P/S ratio

Medacta Group annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Medacta Group shares outstanding

The number of shares was Medacta Group in 2025 — This indicates how many shares 19.972 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2016
20 M base_Shares
Jan 1, 2017
20 M base_Shares
Jan 1, 2018
20 M base_Shares
Jan 1, 2019
20 M base_Shares
Jan 1, 2020
20 M base_Shares
Jan 1, 2021
20 M base_Shares
Jan 1, 2022
20 M base_Shares
Jan 1, 2023
19.99 M base_Shares
Jan 1, 2024
19.96 M base_Shares
Jan 1, 2025
19.97 M base_Shares
Invalid Date
19.97 M base_Shares
Invalid Date
19.97 M base_Shares
Invalid Date
19.97 M base_Shares

Medacta Group Dividend History

4 years of dividend payments · 3 consecutive increases

YearAnnual DividendYoY ChangePayments
20250.35EUR↑ 25.5%1×
May 9, 20250.35EUR↑ 25.5%1/1
20240.28EUR↑ 1.9%1×
20230.27EUR↑ 0.9%1×
20220.27EUR—1×

Medacta Group dividend history and estimates

In 2025, Medacta Group paid a dividend amounting to 0.35 EUR. Dividend means that Medacta Group distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2022
0.27 EUR
0 EUR
Jan 1, 2023
0.27 EUR
0 EUR
Jan 1, 2024
0.28 EUR
0 EUR
Jan 1, 2025
0.35 EUR
0 EUR
Invalid Date
0 EUR
0.62 EUR
Invalid Date
0 EUR
0.72 EUR
Invalid Date
0 EUR
0.6 EUR

Medacta Group dividend payout ratio

In 2025, Medacta Group had a payout ratio of 11.57%. The payout ratio indicates the percentage of the company's profits that Medacta Group distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2016
11.57 %
Jan 1, 2017
11.57 %
Jan 1, 2018
11.57 %
Jan 1, 2019
11.57 %
Jan 1, 2020
11.57 %
Jan 1, 2021
11.57 %
Jan 1, 2022
11.57 %
Jan 1, 2023
11.57 %
Jan 1, 2024
11.57 %
Jan 1, 2025
11.57 %
Invalid Date
11.57 %
Invalid Date
11.57 %
Invalid Date
11.57 %
Price targets and forecasts for Medacta Group are not yet available.

EESG©

Eulerpool ESG Scorecard© for the Medacta Group stock

81/100
99
Environment
99
Social
45
Governance
E

Environment

20
Scope 1 - Direct Emissions1,296
Scope 2 - Indirect emissions from purchased energy620
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions1,916
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees32
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Medacta Group shareholder structure

% Name
69.5484%
Family (Siccardi)
Family (Siccardi)
3.06172%
UBS Fund Management (Switzerland) AG
UBS Fund Management (Switzerland) AG
3.00443%
Artisan Partners Limited Partnership
Artisan Partners Limited Partnership
1.06094%
GAM Investment Management (Switzerland) AG
GAM Investment Management (Switzerland) AG
0.97655%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.74499%
Juno Investment Partners
Juno Investment Partners
0.65519%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
0.65089%
SEB Asset Management (Denmark)
SEB Asset Management (Denmark)
0.58281%
UBS Asset Management (Switzerland)
UBS Asset Management (Switzerland)
0.55016%
Florida State Board of Administration
Florida State Board of Administration
...

Medacta Group Executives and Management Board

FS

Mr. Francesco Siccardi

(47)

Chief Executive Officer, Member of the Group Executive Management

Compensation1.88 M EUR
AS

Mr. Alberto Siccardi

(80)

Non-Executive Chairman of the Board

Compensation325,638 EUR
VB

Mr. Victor Balli

(68)

Non-Executive Lead Independent Director

Compensation214,599 EUR
PW

Mr. Philippe Weber

(59)

Non-Executive Independent Director

Compensation141,250 EUR
MT

Mrs. Maria Siccardi Tonolli

(49)

Non-Executive Director

Compensation127,795 EUR

Frequently asked questions about Medacta Group

Medacta Group SA operates under a medical technology business model. As a leading manufacturer in the orthopedic industry, Medacta specializes in designing, developing, and distributing innovative surgical solutions. The company is primarily focused on providing integrated solutions for joint replacement, spine surgery, and sports medicine. Medacta aims to improve patient outcomes by offering a comprehensive range of products, including implants, instruments, and computer-assisted technologies. With a commitment to research and development, Medacta continuously pushes the boundaries of medical technology, enabling healthcare professionals to deliver advanced and personalized care to patients worldwide.

All fundamentals and in-depth analysis of Medacta Group

Our stock analysis for Medacta Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medacta Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Medacta Group Stock
Medacta Group Revenue→
Medacta Group Stock
Medacta Group Net Income→
Medacta Group Stock
Medacta Group P/E→
Medacta Group Stock
Medacta Group P/S→
Medacta Group Stock
Medacta Group EBIT→
Medacta Group Stock
Medacta Group Dividend→
Medacta Group Stock
Medacta Group Directors Dealings→
Medacta Group Stock
Medacta Group Stocks→
Medacta Group Stock
Medacta Group Market capitalization→
Medacta Group Stock
Medacta Group Debt→
Medacta Group Stock
Medacta Group Liabilities→
Medacta Group Stock
Medacta Group Equity→
Medacta Group Stock
Medacta Group AAQS→
Medacta Group Stock
Medacta Group Employees→
Medacta Group Stock
Medacta Group ROE→
Medacta Group Stock
Medacta Group ROA→
Medacta Group Stock
Medacta Group ROCE→